<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533613475822</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533613475822</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Standards of Practice</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Standards for Nutrition Support</article-title>
<subtitle>Pediatric Hospitalized Patients</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Corkins</surname><given-names>Mark R.</given-names></name>
<degrees>MD, CNSP, FAAP</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Griggs</surname><given-names>Kathleen C.</given-names></name>
<degrees>RN, CNSN</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Groh-Wargo</surname><given-names>Sharon</given-names></name>
<degrees>PhD, RD, LD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Han-Markey</surname><given-names>Theresa L.</given-names></name>
<degrees>MS, RD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Helms</surname><given-names>Richard A.</given-names></name>
<degrees>PharmD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Muir</surname><given-names>Linda V.</given-names></name>
<degrees>MD, RD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Szeszycki</surname><given-names>Elaina E.</given-names></name>
<degrees>PharmD</degrees>
</contrib>
<contrib contrib-type="author">
<collab>Task Force on Standards for Nutrition Support: Pediatric Hospitalized Patients; and the American Society for Parenteral and Enteral Nutrition Board of Directors</collab>
</contrib>
<aff id="aff1-0884533613475822">University of Tennessee Memphis Children’s Medical Center, Tennessee</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0884533613475822">Mark R. Corkins MD, CNSP, FAAP (Chair), University of Tennessee Memphis Children’s Medical Center, 50 N. Dunlap St., Memphis, TN 38103, USA. Email: <email>mcorkins@uthsc.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>2</issue>
<issue-title>Research and Publishing</issue-title>
<fpage>263</fpage>
<lpage>276</lpage>
<permissions>
<copyright-statement>© 2013 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<sec id="section1-0884533613475822" sec-type="intro">
<title>Introduction</title>
<p>The American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) is a professional society of physicians, nurses, dietitians, pharmacists, allied health professionals, and researchers. A.S.P.E.N. envisions an environment in which every patient receives safe, efficacious, and high-quality nutrition care. A.S.P.E.N.’s mission is to improve patient care by advancing the science and practice of clinical nutrition and metabolism. These Standards for Nutrition Support: Pediatric Hospitalized Patients are an update of the 2005 standards. They are intended for use in any hospital setting with or without a formal nutrition support team.</p>
<p>A.S.P.E.N. defines standards as “benchmarks representing a range of performance of competent care that should be provided to ensure safe and efficacious nutrition care.”<sup><xref ref-type="bibr" rid="bibr1-0884533613475822">1</xref></sup> Standards are documents that define the structure needed to provide competent care. Standards usually address professional responsibilities as they relate to patient assessment, diagnosis, education, care plan development, implementation, clinical monitoring, evaluation, and professional issues. A.S.P.E.N. publishes discipline-based (eg, dietitian, nurse, pharmacist, or physician) and practice-based (eg, adult hospitalized patients, pediatric hospitalized patients, home care, long-term care) standards. Standards are presented in the most generic terms possible. The details of specific tests, therapies, and protocols are left to the discretion of individual healthcare facilities. The standards aim to ensure sound and efficient nutrition care for those in need of nutrition support therapy. The application of standards is always subject to the judgment of the professional as applied to the individual case. Separate Clinical Guidelines contain recommendations that are based on evidence from a rigorous systematic review and evaluation of the published medical literature.</p>
<list id="list1-0884533613475822" list-type="order">
<list-item><p>Audience for Standards: These practice-based standards are intended for use by healthcare professionals charged with the care of pediatric patients receiving nutrition support in hospitals.</p></list-item>
<list-item><p>Level of Care: These Standards of Practice present a range of performance of competent care that should be provided by healthcare professionals caring for pediatric patients receiving nutrition support therapy in the hospital environment.</p></list-item></list>
<p>Terminologies included in each standard are specified as:
<list id="list2-0884533613475822" list-type="alpha-lower">
<list-item><p><italic>“Shall”</italic>: indicates standards to be followed strictly.</p></list-item>
<list-item><p><italic>“Should”</italic>: Indicates that among several possibilities, one is particularly suitable, without mentioning or excluding others, or that a certain course of action is preferred but not necessarily required.</p></list-item>
<list-item><p><italic>“May”</italic>: Indicates a course of action that is permissible within the limits of recommended practice.</p></list-item></list></p>
<p>These standards do not constitute medical or other professional advice and should not be taken as such. To the extent that the information published herein may be used to assist in the care of patients, this is the result of the sole professional judgment of the attending healthcare professional whose judgment is the primary component of quality medical care. The information presented in these standards is not a substitute for the exercise of such judgment by the healthcare professional.</p>
<p>These standards have been developed by the Task Force on Standards for Nutrition Support for Pediatric Hospitalized Patients, reviewed by the A.S.P.E.N. Clinical Practice Committee and approved by the A.S.P.E.N. Board of Directors. These Standards of Practice should be used in conjunction with the previously published A.S.P.E.N. Clinical Guidelines and Standards, which can be accessed at the A.S.P.E.N. Documents Library, <ext-link ext-link-type="uri" xlink:href="http://www.nutritioncare.org/Library.aspx">http://www.nutritioncare.org/Library.aspx</ext-link>.</p>
</sec>
<sec id="section2-0884533613475822">
<title>Preface</title>
<p>Pediatric patients and the diseases that lead to their hospitalizations are unique from adult patients. Nutrition is even more important in pediatric patients because they require the substrates for daily metabolism with the added cost of growth.<sup><xref ref-type="bibr" rid="bibr2-0884533613475822">2</xref></sup> Pediatric patients have different percentages of muscle and fat mass and higher resting energy requirements than adults.<sup><xref ref-type="bibr" rid="bibr3-0884533613475822">3</xref></sup> An illness that leads to hospitalization may lead to significant changes in nutrition needs. Malnutrition results in increased immune system vulnerability with greater frequency of infection, higher morbidity and mortality rates, and longer hospital stays.<sup><xref ref-type="bibr" rid="bibr4-0884533613475822">4</xref></sup> Nutrition support in the critically ill child helps reduce the risk of energy and/or protein malnutrition, improves survival, and reduces associated morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr5-0884533613475822">5</xref></sup> The standards presented in this document are intended to provide healthcare professionals with the latest information available to help guide the nutrition care of hospitalized pediatric patients.</p>
</sec>
<sec id="section3-0884533613475822">
<title>CHAPTER I: Organization</title>
<sec id="section4-0884533613475822">
<title>Standard 1. Nutrition Support Team</title>
<p>The critical need for an organized nutrition support team (also known as a nutrition support service) for nutrition assessment, monitoring, and orchestrating nutrition care delivery is supported in the literature.<sup><xref ref-type="bibr" rid="bibr6-0884533613475822">6</xref></sup> Malnutrition in hospitalized children continues to be prevalent in the United States, Europe, and other parts of the world.<sup><xref ref-type="bibr" rid="bibr7-0884533613475822">7</xref><xref ref-type="bibr" rid="bibr8-0884533613475822"/><xref ref-type="bibr" rid="bibr9-0884533613475822"/><xref ref-type="bibr" rid="bibr10-0884533613475822"/><xref ref-type="bibr" rid="bibr11-0884533613475822"/><xref ref-type="bibr" rid="bibr12-0884533613475822"/>-<xref ref-type="bibr" rid="bibr13-0884533613475822">13</xref></sup> Delivering nutrition care services requires coordination of work and collaboration among departments and professional groups. Hospitals that treat pediatric patients should enable and support the services of an interdisciplinary nutrition support team whose mission shall be to identify and oversee nutrition intervention for children determined to be nutritionally at risk.</p>
<list id="list3-0884533613475822" list-type="simple"><list-item><p>1.1. When an organized nutrition support team exists, it shall be directed by a practitioner who, by appropriate education, specialized training, and/or experience, is knowledgeable in delivering nutrition support therapy.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p></list-item>
<list-item><p>1.2. An organized nutrition support team should include a dietitian, nurse, pharmacist, and physician, each following standards of practice for their discipline.<sup><xref ref-type="bibr" rid="bibr15-0884533613475822">15</xref><xref ref-type="bibr" rid="bibr16-0884533613475822"/><xref ref-type="bibr" rid="bibr17-0884533613475822"/>-<xref ref-type="bibr" rid="bibr18-0884533613475822">18</xref></sup></p></list-item>
<list-item><p>1.3. If a nutrition support team is not established, nutrition support therapy should be managed by an interdisciplinary approach and should include the patient’s physician, nurse, dietitian, and pharmacist.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p></list-item>
<list-item><p>1.4. Healthcare professionals involved with providing nutrition support to pediatric patients shall be competent to assess the nutrition status, determine the appropriate use of nutrition support, and manage the nutrition support therapy of that population. Nutrition support certification may be considered ideal to document necessary level of knowledge and skills to provide the highest-quality care.</p></list-item></list>
</sec>
<sec id="section5-0884533613475822">
<title>Standard 2. Policies and Procedures</title>
<p>Written policies and procedures for providing nutrition support therapy shall be established.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p>
<list id="list4-0884533613475822" list-type="simple"><list-item><p>2.1. The policies and procedures shall be developed with the input and review of all members of the nutrition support team.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p></list-item>
<list-item><p>2.2. The policies and procedures shall be periodically reviewed and revised as appropriate to optimize patient care.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p></list-item></list>
</sec>
<sec id="section6-0884533613475822">
<title>Standard 3. Performance Improvement</title>
<p>The nutrition support team or ad hoc interdisciplinary group shall review and report on team performance, patient outcome data, and cost of services.<sup><xref ref-type="bibr" rid="bibr19-0884533613475822">19</xref></sup></p>
<list id="list5-0884533613475822" list-type="simple"><list-item><p>3.1. The review of performance should assess the appropriateness and effectiveness of administering nutrition support therapy to individual patients.</p></list-item>
<list-item><p>3.2. Performance improvement mechanisms should provide a means to initiate policy, procedure, and/or protocol changes that enhance the safety and efficacy of nutrition therapy for hospitalized pediatric patients.</p></list-item></list>
</sec></sec>
<sec id="section7-0884533613475822">
<title>CHAPTER II: Nutrition Care</title>
<p>Healthcare professionals are faced with hospitalized pediatric patients who run the spectrum from underweight to overweight. Developing a nutrition care plan requires an accommodation for preexisting nutrition status plus the pediatric requirements for growth in the presence of a medical condition that will change with intervention.<sup><xref ref-type="bibr" rid="bibr20-0884533613475822">20</xref><xref ref-type="bibr" rid="bibr21-0884533613475822"/>-<xref ref-type="bibr" rid="bibr22-0884533613475822">22</xref></sup></p>
<p>The nutrition care process and administering nutrition support therapy require a series of steps with feedback loops. These steps include nutrition screening, nutrition assessment, formulating and implementing a nutrition care plan, patient monitoring, evaluating the plan, evaluating the care setting, and then either reformulating the care plan or terminating therapy. The nutrition care algorithm is illustrated in <xref ref-type="fig" rid="fig1-0884533613475822">Figure 1</xref>.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p>
<fig id="fig1-0884533613475822" position="float">
<label>Figure 1.</label>
<caption>
<p>Nutrition care algorithm. Reprinted from Ukleja A, Freeman KL, Gilbert K, et al; Task Force on Standards for Nutrition Support: Adult Hospitalized Patients and the American Society for Parenteral and Enteral Nutrition Board of Directors. Standards for nutrition support: adult hospitalized patients. <italic>Nutr Clin Pract</italic>. 2010;25(4):403-414.</p>
</caption>
<graphic xlink:href="10.1177_0884533613475822-fig1.tif"/></fig>
<sec id="section8-0884533613475822">
<title>Standard 4. Nutrition Screening</title>
<p>The primary purpose of pediatric nutrition screening is to determine if a pediatric patient is nutritionally at risk and whether a detailed pediatric nutrition assessment is indicated. Patients who are nutritionally at risk shall be identified by nutrition screening using specific criteria within 24 hours of hospital admission and periodic rescreening. No single biochemical parameter shall serve as a nutrition screening tool.</p>
<list id="list6-0884533613475822" list-type="simple"><list-item><p>4.1. The policy and procedure for nutrition screening shall be formalized and documented.<list id="list7-0884533613475822" list-type="simple">
<list-item><p>4.1.1. All patients shall be screened for nutrition risk within 24 hours after admission.<sup><xref ref-type="bibr" rid="bibr23-0884533613475822">23</xref></sup></p></list-item>
<list-item><p>4.1.2. The result of the nutrition screen shall be documented and appropriate intervention initiated.</p></list-item>
<list-item><p>4.1.3. A procedure for nutrition rescreening shall be implemented.</p></list-item></list></p></list-item>
</list>
</sec>
<sec id="section9-0884533613475822">
<title>Standard 5. Nutrition Assessment</title>
<p>All pediatric patients identified as nutritionally at risk shall undergo a nutrition assessment. The intent of the nutrition assessment is to document baseline nutrition parameters, determine nutrition risk factors, identify specific nutrition deficits, establish nutrition needs for individual patients, and identify medical, psychosocial, and socioeconomic factors that may influence the prescribing and administering of nutrition support therapy.<sup><xref ref-type="bibr" rid="bibr23-0884533613475822">23</xref><xref ref-type="bibr" rid="bibr24-0884533613475822"/><xref ref-type="bibr" rid="bibr25-0884533613475822"/><xref ref-type="bibr" rid="bibr26-0884533613475822"/>-<xref ref-type="bibr" rid="bibr27-0884533613475822">27</xref></sup> This nutrition assessment shall be documented and available to all healthcare providers.</p>
<list id="list8-0884533613475822" list-type="simple"><list-item><p>5.1. The nutrition assessment shall be performed within a timely manner as specified by institutional policy by or under the supervision of a registered dietitian with pediatric experience or in conjunction with other healthcare professionals with pediatric nutrition expertise.</p></list-item>
<list-item><p>5.2. The nutrition assessment shall include assessment of the patient’s current nutrition status and nutrition requirements as specified below.</p></list-item>
<list-item><p>5.3. The pediatric patient’s nutrition requirements should include energy, macronutrient (protein, carbohydrate, and fat), fluid, electrolyte, and micronutrient requirements. These findings should be interpreted using pediatric normal laboratory values.<sup><xref ref-type="bibr" rid="bibr28-0884533613475822">28</xref></sup></p></list-item>
<list-item><p>5.4. Nutrition assessment shall include review and documenting factors relevant to delivering nutrition support therapy. Relevant factors may include, but are not limited to, the following: detailed feeding history, aspiration risk assessment, psychosocial and socioeconomic factors, gastrointestinal tract function, enteral and vascular access, and schedule of diagnostic and invasive procedures.</p></list-item>
<list-item><p>5.5. Nutrition assessment shall include review and documenting growth using age- and disease-specific charts, as indicated. Refer to <xref ref-type="table" rid="table1-0884533613475822">Table 1</xref> for growth chart references for several specific medical conditions and syndromes.<sup><xref ref-type="bibr" rid="bibr29-0884533613475822">29</xref></sup></p></list-item></list>
<table-wrap id="table1-0884533613475822" position="float">
<label>Table 1.</label>
<caption>
<p>Growth Chart References for Specific Medical Conditions and Syndromes.<sup><xref ref-type="bibr" rid="bibr29-0884533613475822">29</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0884533613475822" xlink:href="10.1177_0884533613475822-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Medical Condition</th>
<th align="center">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm infant</td>
<td>Olsen, IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. <italic>Pediatrics</italic>. 2010;e214-e224.</td>
</tr>
<tr>
<td/>
<td>Fenton TR. A new growth chart for preterm babies: Babson and Benda’s chart updated with recent data and a new format. <italic>BMC Pediatr</italic>. 2003;3:13.</td>
</tr>
<tr>
<td/>
<td>Ehrenkranz RA, Younes N, Lemons JA, et al. Longitudinal growth of hospitalized very low birth weight infants. <italic>Pediatrics</italic>. 1999;104(2):280-289.</td>
</tr>
<tr>
<td/>
<td>Lubchenco LO, Hansman C, Boyd E. Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 42 weeks. <italic>Pediatrics</italic>. 1966;37(3):403-408.</td>
</tr>
<tr>
<td/>
<td>Lubchenco LO, Hansman C, Dressler M, Boyd E. Intrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestation. <italic>Pediatrics</italic>. 1963;32(5):793-800.</td>
</tr>
<tr>
<td>Normal term infant (birth to age 2 years)</td>
<td>WHO Multicentre Growth Reference Study Group. Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. WHO Child Growth Standards. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/childgrowth/en/">http://www.who.int/childgrowth/en/</ext-link>. Published 2006. Accessed November 26, 2012.</td>
</tr>
<tr>
<td>Childhood/adolescence (age 2 years to 20 years)</td>
<td>Centers for Disease Control and Prevention, National Center for Health Statistics. CDC growth charts: United States. <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/growthcharts/">http://www.cdc.gov/growthcharts/</ext-link>. Accessed May 30, 2000.</td>
</tr>
<tr>
<td>Achondroplasia</td>
<td>Horton WA, Rotter JI, Rimoin DL, Scott CI, Hall JG. Standard growth curves for achondroplasia. <italic>J Pediatr</italic>. 1978;93(3):435-438.</td>
</tr>
<tr>
<td>Cerebral palsy</td>
<td>Brooks J, Day S, Shavelle R, Strauss D. Low weight, morbidity, and mortality in children with cerebral palsy: new clinical growth charts. <italic>Pediatrics</italic>. 2011;128(2):e299-e307.</td>
</tr>
<tr>
<td>Down’s syndrome</td>
<td>Myrelid A, Gustafsson J, Ollars B, Annerén G. Growth charts for Down’s syndrome from birth to 18 years of age. <italic>Arch Dis Child</italic>. 2002;87(2):97-103.</td>
</tr>
<tr>
<td>Duchenne muscular dystrophy</td>
<td>Griffiths RD, Edwards RH. A new chart for weight control in Duchenne muscular dystrophy. <italic>Arch Dis Child</italic>. 1988;63:1256-1258.</td>
</tr>
<tr>
<td>Noonan syndrome</td>
<td>Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR. Noonan syndrome: growth and clinical manifestations in 144 cases. <italic>Eur J Pediatr</italic>. 1988;148(3):220-227.</td>
</tr>
<tr>
<td>Prader-Willi syndrome</td>
<td>Hauffa BP, Schlippe G, Roos M, Gillessen-Kaesbach G, Gasser T. Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome. <italic>Acta Paediatr</italic>. 2000;89(11):1302-1311.</td>
</tr>
<tr>
<td>Silver-Russell syndrome</td>
<td>Wollmann HA, Kirchner T, Enders H, Preece MA, Ranke MB. Growth and symptoms in Silver-Russell syndrome: review on the basis of 386 patients. <italic>Eur J Pediatr</italic>. 1995;154(12):958-968.</td>
</tr>
<tr>
<td>Turner’s syndrome</td>
<td>Rongen-Westerlaken C, Corel L, van den Broeck J, et al. Reference values for height, height velocity and weight in Turner’s syndrome. <italic>Acta Paediatr</italic>. 1997;86(9):937-942.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533613475822"><p>For an online training course, see “Using the WHO Growth Charts to Assess Growth in the United States Among Children Ages Birth to 2 Years” (<ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/nccdphp/dnpao/growthcharts/who/index.htm">http://www.cdc.gov/nccdphp/dnpao/growthcharts/who/index.htm</ext-link>).</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section10-0884533613475822">
<title>CHAPTER III: Developing a Nutrition Care Plan</title>
<sec id="section11-0884533613475822">
<title>Standard 6. Objectives</title>
<p>The nutrition care plan is the template for nutrition therapy and is created by analysis of information from many aspects of care, including consultations, therapies, and assessments. The nutrition care plan is a formal statement of the nutrition goals and interventions prescribed for an individual using the data obtained from a nutrition assessment. The plan should include statements of nutrition goals and monitoring/evaluation parameters, the most appropriate administration route of nutrition therapy, nutrition access, anticipated duration of therapy, and training and counseling goals and methods.<sup><xref ref-type="bibr" rid="bibr1-0884533613475822">1</xref></sup></p>
</sec>
<sec id="section12-0884533613475822">
<title>Standard 7. Interdisciplinary Approach</title>
<p>The nutrition care plan should be developed using an interdisciplinary team approach involving the patient and family, nutrition support team, the patient’s physician(s), dietitian(s), and other appropriate healthcare professionals with pediatric experience. The nutrition care plan should be developed using a family-centered approach.</p>
</sec>
<sec id="section13-0884533613475822">
<title>Standard 8. Goals and Expectations</title>
<p>The nutrition care plan shall address patient/caregiver goals and expectations, document patient/caregiver comprehension of recommended nutrition support therapy, and include patient/caregiver wishes.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup> Benchmarks should be established to identify progress toward the desired outcome of therapy and provide objective evidence that the nutrition care plan is providing optimal, appropriate, and resource-efficient care. The nutrition care plan should also establish a family-centered, patient-specific set of goals that can be used to continually assess the efficacy of therapy and adequacy of growth. Appropriate routes of administration shall be defined, identification of intake goals shall be included, and estimated duration of therapy, as well as criteria for discontinuation of therapy, should be discussed.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p>
</sec>
<sec id="section14-0884533613475822">
<title>Standard 9. Selection of Route</title>
<p>The route selected to provide nutrition support therapy shall be appropriate to the patient’s medical condition and should be reassessed periodically for continued appropriateness, as well as its adequacy in meeting goals of the nutrition care plan (see <xref ref-type="fig" rid="fig2-0884533613475822">Figure 2</xref>).<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p>
<fig id="fig2-0884533613475822" position="float">
<label>Figure 2.</label>
<caption>
<p>Route of administration algorithm. EN, enteral nutrition; GI, gastrointestinal; PN, parenteral nutrition. Adapted from Ukleja A, Freeman KL, Gilbert K, et al; Task Force on Standards for Nutrition Support: Adult Hospitalized Patients and the American Society for Parenteral and Enteral Nutrition Board of Directors. Standards for nutrition support: adult hospitalized patients. <italic>Nutr Clin Pract</italic>. 2010;25(4):403-414.</p>
</caption>
<graphic xlink:href="10.1177_0884533613475822-fig2.tif"/></fig>
<list id="list9-0884533613475822" list-type="simple"><list-item><p>9.1. Enteral nutrition (EN) should be used in preference to parenteral nutrition (PN) to the greatest extent possible.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p></list-item>
<list-item><p>9.2. PN should be used when the gastrointestinal tract is not functional or cannot be accessed, or the patient’s nutrient needs are greater than those that can be met through the gastrointestinal tract.</p></list-item>
<list-item><p>9.3. Oral stimulation should be initiated when children have no or limited oral intake during the first 2 years of life in order to enhance feeding skills and speech.<sup><xref ref-type="bibr" rid="bibr30-0884533613475822">30</xref></sup></p></list-item></list>
</sec>
<sec id="section15-0884533613475822">
<title>Standard 10. Selection of Formulation</title>
<p>The EN or PN formulation shall be appropriate for the patient’s disease process and compatible with the route of access.</p>
<list id="list10-0884533613475822" list-type="simple"><list-item><p>10.1. The EN or PN formulation shall be adjusted as appropriate in patients with growth failure and/or organ dysfunction.</p></list-item>
<list-item><p>10.2. When significant amounts of nutrients are provided through means other than the EN/PN formulation (eg, parenteral infusions, medications, fluids, renal replacement therapy), the formulation should be adjusted accordingly.</p></list-item>
<list-item><p>10.3. All fluid sources should be considered when determining the patient’s nutrition prescription.</p></list-item></list>
</sec></sec>
<sec id="section16-0884533613475822">
<title>CHAPTER IV: Implementation</title>
<sec id="section17-0884533613475822">
<title>Standard 11. Ordering Process</title>
<p>Implementing the nutrition care plan shall follow nutrition assessment and development of a formal nutrition care plan.</p>
<list id="list11-0884533613475822" list-type="simple"><list-item><p>11.1. Implementing a nutrition care plan shall have a defined standardized ordering process via hard copy or computerized prescriber order entry (CPOE).<list id="list12-0884533613475822" list-type="simple">
<list-item><p>11.1.1. Prescriptions/orders for food or nutrition support therapy products shall be documented in the patient’s medical record before administration.<sup><xref ref-type="bibr" rid="bibr31-0884533613475822">31</xref></sup></p></list-item></list>
</p></list-item>
</list>
</sec>
<sec id="section18-0884533613475822">
<title>Standard 12. Nutrition Support Access</title>
<p>Access for nutrition support therapy shall be achieved and maintained in a manner that minimizes risk to the patient.<sup><xref ref-type="bibr" rid="bibr23-0884533613475822">23</xref>,<xref ref-type="bibr" rid="bibr25-0884533613475822">25</xref>,<xref ref-type="bibr" rid="bibr27-0884533613475822">27</xref></sup></p>
<list id="list13-0884533613475822" list-type="simple"><list-item><p>12.1. Access devices shall be placed by or under the supervision of a physician, nurse, or specially trained healthcare professional who is proficient in placement of access devices in children and who is competent and knowledgeable in recognizing and managing complications associated with placing and maintaining access devices.</p></list-item>
<list-item><p>12.2. Access devices shall be placed safely, effectively, and humanely in children. For vascular access placement, methods for appropriate sedation or anesthesia, use of sterile technique, and selection of appropriate catheter size and material shall be defined.</p></list-item>
<list-item><p>12.3. Standard techniques and protocols shall be established and followed for inserting access devices and routine care.</p></list-item>
<list-item><p>12.4. Proper placement of vascular and enteral access devices shall be appropriately confirmed and documented in the medical record prior to use. For neonates and infants, regular assessment of placement shall be required after insertion to ensure proper placement is maintained.<list id="list14-0884533613475822" list-type="simple">
<list-item><p>12.4.1. Central venous access shall be obtained prior to administering central PN. The catheter tip should be positioned in the distal portion of the superior vena cava or at the superior vena cava adjacent to the right atrium.<sup><xref ref-type="bibr" rid="bibr32-0884533613475822">32</xref></sup> Femoral central lines are not recommended for central PN but may be used under emergent conditions.</p></list-item>
<list-item><p>12.4.2. Peripheral venous access is intended for short-term nutrition support therapy and generally should not be used for longer than 7 to 10 days. If longer nutrition support therapy is required, then a central venous access device shall be inserted.<sup><xref ref-type="bibr" rid="bibr33-0884533613475822">33</xref></sup></p></list-item>
</list></p></list-item>
<list-item><p>12.5. Complications related to an access device and outcome of actions to manage the complications shall be clearly documented in the medical record.</p></list-item>
<list-item><p>12.6. The access device used for nutrition support therapy should be used only for nutrition therapies on a routine basis unless an emergent need arises. Routine blood draws, medication delivery, and other fluids should not be infused or co-infused in the venous access devices used for nutrition support therapy.</p></list-item></list>
</sec>
<sec id="section19-0884533613475822">
<title>Standard 13. Parenteral Nutrition Formulation Preparation</title>
<p>PN formulations shall be prepared accurately and safely as prescribed.</p>
<list id="list15-0884533613475822" list-type="simple"><list-item><p>13.1. PN formulations shall be prepared using current and established policies and procedures regarding sterile compounding, compatibility, stability, and labeling.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup> These procedures shall be supervised by a licensed pharmacist, and the institution should have available United States Pharmacopeial Convention (USP) <italic>USP &lt;797&gt;: Pharmaceutical Compounding—Sterile Preparation</italic> for all staff engaged in PN formulation preparation, storage, delivery, and administration.<sup><xref ref-type="bibr" rid="bibr35-0884533613475822">35</xref></sup></p></list-item>
<list-item><p>13.2. Automated equipment used for the preparation of PN formulations shall be cared for properly within an appropriately designed and constructed sterile products room, ISO class 5 cleanroom, all with environmental quality control as described in USP &lt;797&gt;.<sup><xref ref-type="bibr" rid="bibr35-0884533613475822">35</xref></sup><list id="list16-0884533613475822" list-type="simple">
<list-item><p>13.2.1. Policies and procedures for the use of automated compounding devices (ACDs) for PN formulations shall be developed to address responsibilities for operation, calibration and maintenance, staff training, and testing and monitoring compounder performance at all times.<sup><xref ref-type="bibr" rid="bibr36-0884533613475822">36</xref></sup></p></list-item>
<list-item><p>13.2.2. Personnel shall be trained in proper operation, calibration, and maintenance of the equipment. Additionally, personnel will undergo routine preparation validation through media-fill testing.</p></list-item>
<list-item><p>13.2.3. Personnel shall be trained to use computer software with appropriate content limits for pediatric formulations to assist in daily use and troubleshooting of ACDs.</p></list-item>
<list-item><p>13.2.4. Documents generated by the ACD shall be compared with the hard copy or CPOE PN formulation order.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p></list-item>
<list-item><p>13.2.5. The operator shall monitor the ACD continuously during the preparation process to ensure the proper operation of the equipment, including verification of accuracy and sterility (pyrogen testing is recommended for high-risk Compounded Sterile Products).</p></list-item>
</list></p></list-item>
<list-item><p>13.3. PN formulations shall be sterile.<list id="list17-0884533613475822" list-type="simple">
<list-item><p>13.3.1. PN formulations shall be prepared in a laminar or vertical airflow hood within a sterile products room of appropriate ISO class by an individual trained in aseptic technique under the direction of or by a licensed pharmacist.</p></list-item>
<list-item><p>13.3.2. The preparation area shall be a class 100 (ISO 5) environment with limited access to decrease the potential for microbial contamination.<sup><xref ref-type="bibr" rid="bibr35-0884533613475822">35</xref></sup></p></list-item>
<list-item><p>13.3.3. Aseptic technique shall be taught, including garbing, aseptic work practices, cleaning, and disinfection. The aseptic techniques used should be validated on a periodic and routine basis.</p></list-item>
<list-item><p>13.3.4. Sterility testing shall be performed on a regular surveillance basis.</p></list-item>
</list></p></list-item>
<list-item><p>13.4. PN formulations shall be visually inspected to identify signs of gross contamination, particle formation, or phase separation during the preparation process, during storage, and before and during administration.</p></list-item>
<list-item><p>13.5. If repackaging from the original containers of intravenous (IV) fat emulsions is conducted, methods shall be taken to promote sterility, including preparation in a laminar or vertical airflow hood and using appropriate infusion hang times.<sup><xref ref-type="bibr" rid="bibr37-0884533613475822">37</xref></sup></p></list-item>
<list-item><p>13.6. All PN formulations shall be prepared in compatible containers. Methods should be taken to limit the aluminum contamination in PN formulations.<sup><xref ref-type="bibr" rid="bibr38-0884533613475822">38</xref>,<xref ref-type="bibr" rid="bibr39-0884533613475822">39</xref></sup></p></list-item></list>
</sec>
<sec id="section20-0884533613475822">
<title>Standard 14. Enteral Nutrition Formulation Preparation</title>
<p>EN formulations including human breast milk (HBM) and infant formulas shall be prepared accurately and safely as prescribed.</p>
<list id="list18-0884533613475822" list-type="simple"><list-item><p>14.1. HBM shall be prepared, labeled, stored, and discarded using current and published guidelines established by the American Dietetic Association (now the Academy of Nutrition and Dietetics) and the Human Milk Banking Association of North American (HMBANA).<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref>,<xref ref-type="bibr" rid="bibr41-0884533613475822">41</xref></sup> These procedures shall be supervised by a registered dietitian, registered nurse, certified lactation consultant, or other qualified healthcare professional, and the institution should have <italic>Infant Feedings: Guidelines for Preparation of Human Milk and Formula in Health Care Facilities</italic> available for all staff engaged in human milk administration.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup><list id="list19-0884533613475822" list-type="simple">
<list-item><p>14.1.1. Guidelines shall exist for the expression, storage, and handling of expressed HBM.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref><xref ref-type="bibr" rid="bibr41-0884533613475822"/>-<xref ref-type="bibr" rid="bibr42-0884533613475822">42</xref></sup></p></list-item>
<list-item><p>14.1.2. Guidelines shall exist for the use of donor HBM as a feeding alternative for infants whose mothers are unable to provide HBM. Donor HBM shall be pasteurized.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup></p></list-item>
</list></p></list-item>
<list-item><p>14.2. EN formulations including commercial infant formulas shall be prepared, labeled, stored, and discarded according to the manufacturer’s recommendations and using current and published guidelines.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup> These procedures shall be supervised by a registered dietitian or other qualified healthcare professional, and the institution should have <italic>Infant Feedings: Guidelines for Preparation of Human Milk and Formula in Health Care Facilities</italic> available for all staff engaged in EN formulation preparation.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup><list id="list20-0884533613475822" list-type="simple">
<list-item><p>14.2.1. Commercially sterile, ready-to-feed, or liquid concentrate formulas shall be prepared using aseptic technique. For patients in neonatal intensive care settings, for neonatal and infant patients, and for those who may be immunocompromised, commercially sterile ready-to-feed and liquid-concentrate formulas should be used when available and nutritionally appropriate. The powder form of an infant formula should be used <italic>only</italic> when alternative commercially sterile liquid products are not available.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup></p></list-item>
<list-item><p>14.2.2. Liquid-concentrate and powder infant formulas should be reconstituted with chilled, commercially sterile ingredient water.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref>,<xref ref-type="bibr" rid="bibr42-0884533613475822">42</xref></sup></p></list-item>
</list></p></list-item>
<list-item><p>14.3. A quality control plan following Hazard Analysis Critical Control Point (HACCP) guidelines should be developed to ensure and assess sanitary techniques in the preparation, handling, storage, and administration of EN formulations.<sup><xref ref-type="bibr" rid="bibr43-0884533613475822">43</xref><xref ref-type="bibr" rid="bibr44-0884533613475822"/>-<xref ref-type="bibr" rid="bibr45-0884533613475822">45</xref></sup><list id="list21-0884533613475822" list-type="simple">
<list-item><p>14.3.1. A separate room should be available for the preparation of infant formula, HBM, and enteral feedings. In facilities where that is not possible, a dedicated clean space, away from the patient’s bedside, with facilities for aseptic technique should be available.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup></p></list-item>
<list-item><p>14.3.2. Preparation equipment shall be sanitized regularly according to institutional guidelines. Upright blenders should not be used for HBM or EN formulation preparation.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup></p></list-item>
</list></p></list-item>
<list-item><p>14.4. Guidelines should exist that delineate the institution’s response to a preparation error or a manufacturer’s recall of an infant formula or enteral formulation.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup></p></list-item></list>
</sec>
<sec id="section21-0884533613475822">
<title>Standard 15. Additives</title>
<p>Products added to a PN formulation shall be appropriate and compatible with all ingredients and shall be added safely and accurately.</p>
<list id="list22-0884533613475822" list-type="simple"><list-item><p>15.1. All PN ingredients/components shall be listed on the label.</p></list-item>
<list-item><p>15.2. Healthcare professionals responsible for the preparation and delivery of PN formulations shall employ methods for detection and prevention of formulation incompatibilities.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup><list id="list23-0884533613475822" list-type="simple">
<list-item><p>15.2.1. All additions to a PN formulation shall be made in a laminar or vertical airflow hood within a sterile products room under the direct supervision of or by a licensed pharmacist.<sup><xref ref-type="bibr" rid="bibr35-0884533613475822">35</xref></sup></p></list-item>
<list-item><p>15.2.2. Individuals who inject additives into PN formulations shall be trained in proper sterile technique.</p></list-item>
<list-item><p>15.2.3. The addition of medications or other nutrients to PN formulations after they have left the pharmacy shall not be done.</p></list-item>
</list></p></list-item>
<list-item><p>15.3. Protocols or software revisions for PN formulators shall be established to define acceptable warning limits of specific nutrients and additives in PN formulations.<sup><xref ref-type="bibr" rid="bibr46-0884533613475822">46</xref></sup></p></list-item>
<list-item><p>15.4. The sequence of addition of calcium and phosphorus to PN formulations should be optimized to prevent calcium phosphate precipitation.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup><list id="list24-0884533613475822" list-type="simple">
<list-item><p>15.4.1. Calcium gluconate is the preferred calcium salt and should be used in PN formulations.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref>,<xref ref-type="bibr" rid="bibr46-0884533613475822">46</xref>,<xref ref-type="bibr" rid="bibr47-0884533613475822">47</xref></sup></p></list-item>
<list-item><p>15.4.2. Phosphorus salts shall be added to the PN formulation before any other formulation additive.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup></p></list-item>
<list-item><p>15.4.3. Calcium should be added near the end of the compounding sequence to take advantage of the maximum volume of the PN formulation.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup></p></list-item>
<list-item><p>15.4.4. Some amino acid products contain phosphate ions. This additional amount of phosphate should be accounted for in the calculation of calcium phosphate solubility.</p></list-item></list></p></list-item>
<list-item><p>15.5. When IV medications emergently need to be co-infused, policies and procedures should be developed to guide caregivers as to safe practices for co-infusion of medications, electrolytes and minerals, and PN formulation.</p></list-item>
<list-item><p>15.6. Deviation from established policies and procedures should require approval by a healthcare professional who is knowledgeable about physical-chemical compatibilities, drug-drug, and drug-nutrient interactions.</p></list-item>
<list-item><p>15.7. All pediatric patients receiving PN should receive daily parenteral multivitamins in quantities established by the Subcommittee on Pediatric Parenteral Nutrition Requirements from the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition (now American Society for Nutrition).<sup><xref ref-type="bibr" rid="bibr48-0884533613475822">48</xref></sup> Dosing may need to be adjusted in severe renal and hepatic dysfunction, excessive losses, or in patients receiving long-term PN. In the event of parenteral multivitamin product shortage, multivitamin use may need to be adjusted per patient population. Institutions should follow the considerations for multivitamin administration during shortages as set forth by A.S.P.E.N.<sup><xref ref-type="bibr" rid="bibr49-0884533613475822">49</xref></sup></p></list-item>
<list-item><p>15.8. All pediatric patients receiving PN should receive daily parenteral trace elements in quantities established by the Subcommittee on Pediatric Parenteral Nutrition Requirements from the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition (now American Society for Nutrition).<sup><xref ref-type="bibr" rid="bibr48-0884533613475822">48</xref></sup> Dosing shall be adjusted for severe renal and hepatic dysfunction, excessive losses, or in patients receiving long-term PN. In the event of a parenteral multiple trace element product shortage, trace elements should be dosed individually. Institutions should follow the considerations for trace element administration during shortages as set forth by A.S.P.E.N.<sup><xref ref-type="bibr" rid="bibr50-0884533613475822">50</xref></sup></p></list-item>
<list-item><p>15.9. Components added to EN formulations shall be appropriate and compatible with all ingredients and shall be added safely and accurately.<list id="list25-0884533613475822" list-type="simple">
<list-item><p>15.9.1. Healthcare professionals responsible for the preparation and delivery of EN formulations shall employ methods for detection and prevention of formulation incompatibilities.</p></list-item>
<list-item><p>15.9.2. Protocols should be established to define acceptable minimum and maximum amounts of specific nutrients in EN formulations.</p></list-item>
<list-item><p>15.9.3. Policies and procedures shall be established regarding subsequent additions to EN formulations, including dilution of formula and addition of medications. Any additions to the formulation shall be ordered by the prescribing practitioner or designee and documented by the formulating personnel in the medical record and should be consistent with published guidelines.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref>,<xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref>,<xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup></p></list-item>
<list-item><p>15.9.3.1. Nutrient additives should be added in the formula room or breast milk preparation area. EN additives shall not be weighed or measured at the bedside but should be prepackaged by pharmacy.</p></list-item>
<list-item><p>15.9.3.2. All additives shall be included as part of the EN label.<sup><xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup></p></list-item>
<list-item><p>15.9.3.3. Colorants (food coloring and methylene blue) shall not be added to EN.<sup><xref ref-type="bibr" rid="bibr50-0884533613475822">50</xref>,<xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup> Blue dyes have been used in feedings to detect aspiration visually. The safety, sensitivity, and specificity of blue-tinted EN have not been documented.<sup><xref ref-type="bibr" rid="bibr52-0884533613475822">52</xref><xref ref-type="bibr" rid="bibr53-0884533613475822"/><xref ref-type="bibr" rid="bibr54-0884533613475822"/><xref ref-type="bibr" rid="bibr55-0884533613475822"/><xref ref-type="bibr" rid="bibr56-0884533613475822"/>-<xref ref-type="bibr" rid="bibr57-0884533613475822">57</xref></sup> Case reports have associated the use of FD&amp;C Blue No. 1 with serious adverse events and death, although a direct causal relationship has not been proven.<sup><xref ref-type="bibr" rid="bibr58-0884533613475822">58</xref><xref ref-type="bibr" rid="bibr59-0884533613475822"/><xref ref-type="bibr" rid="bibr60-0884533613475822"/><xref ref-type="bibr" rid="bibr61-0884533613475822"/>-<xref ref-type="bibr" rid="bibr62-0884533613475822">62</xref></sup> Methylene blue toxicity has also been described.<sup><xref ref-type="bibr" rid="bibr63-0884533613475822">63</xref></sup> Microbial contamination of feedings has been associated with the use of dye dispensed from multiple-dose containers.<sup><xref ref-type="bibr" rid="bibr64-0884533613475822">64</xref></sup></p></list-item></list>
</p></list-item>
</list>
</sec>
<sec id="section22-0884533613475822">
<title>Standard 16. Packaging and Labeling</title>
<p>PN and EN formulations shall be appropriately packaged and labeled.</p>
<list id="list26-0884533613475822" list-type="simple"><list-item><p>16.1. PN formulation shall be packaged in administration containers that can ensure maintenance of sterility and allow visual inspection during preparation, storage, and administration.<list id="list27-0884533613475822" list-type="simple">
<list-item><p>16.1.1. The PN formulations shall be labeled and the content and format of a PN label shall follow the Standard Label Format for Neonates or Pediatrics as recommended by the Task Force for the Revision of Safe Practices for Parenteral Nutrition or as dictated by state laws.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup> The PN formulation label should contain a statement indicating that it is for parenteral administration only.</p></list-item>
<list-item><p>16.1.2. The PN formulation shall be stored in a refrigerator (according to established guidelines) unless the formulation will be administered immediately to the patient.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup></p></list-item>
</list></p></list-item>
<list-item><p>16.2. EN formulations shall be packaged in administration containers, which ensure accuracy of volume and cleanliness and minimize the risk for contamination. Refer to A.S.P.E.N. Enteral Nutrition Practice Recommendations.<sup><xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup><list id="list28-0884533613475822" list-type="simple">
<list-item><p>16.2.1. Refer to Standard 14 for additional information regarding packaging and labeling of HBM and infant formulas.</p></list-item>
<list-item><p>16.2.2. Open-system administration containers should be used if the EN formulation will be modified with modular products.</p></list-item>
<list-item><p>16.2.3. Hospital-prepared EN formulations shall be stored in a refrigerator (per established guidelines) unless the formulation will be administered immediately to the patient.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref>,<xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup></p></list-item>
</list></p></list-item>
<list-item><p>16.3. EN formulation administration containers shall be labeled accurately with the contents and patient information. Refer to A.S.P.E.N. Enteral Nutrition Practice Recommendations.<sup><xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup><list id="list29-0884533613475822" list-type="simple">
<list-item><p>16.3.1. EN labels should be standardized, containing all elements of the order.</p></list-item>
<list-item><p>16.3.2. EN formulation administration containers should be labeled with the patient’s name, medical record identification number, product name and strength, additives, volume, and beyond-use date and hang time.</p></list-item>
<list-item><p>16.3.3. EN formulation labels should contain delivery site/access and route (enteral), and method of administration.</p></list-item>
<list-item><p>16.3.4. EN formulation labels should contain a statement indicating a formulation is for enteral administration only.</p></list-item></list></p></list-item>
</list>
</sec>
<sec id="section23-0884533613475822">
<title>Standard 17. Administration of Nutrition Support Therapy Formulations</title>
<p>EN and PN formulations shall be administered safely and accurately in accordance with the prescribed order and consistent with the patient’s tolerance.</p>
<list id="list30-0884533613475822" list-type="simple"><list-item><p>17.1. Hospital-specific protocols and procedures shall exist regarding techniques used to administer nutrition support therapy. Ideally, these protocols/procedures should be developed by a nutrition support team or committee with expertise in nutrition support therapy. The identified group shall be responsible for periodic review and update of these specific protocols and procedures.</p></list-item>
<list-item><p>17.2. Nutrition support therapy formulations shall be administered by or under the supervision of trained personnel; administration and tolerance shall be documented in the medical record.</p></list-item>
<list-item><p>17.3. Prior to administering the formulation to the patient, the label on the formulation shall be checked against the prescribed order and the patient’s identity shall be verified per hospital policy to ensure the prescribed formulation is delivered to the appropriate patient and administered by the correct route and for the designated/intended time.</p></list-item>
<list-item><p>17.4. The administration rate of the prescribed formulation shall be checked each time a new volume of formulation is ordered or initiated, before resuming an interrupted infusion, and periodically during its administration.</p></list-item>
<list-item><p>17.5. Protocols shall be written to prevent and manage vascular or enteral access device occlusion.</p></list-item>
<list-item><p>17.6. Each PN formulation shall be inspected prior to and during administration. If visual changes are present, the formulation shall not be administered and the appropriate pharmacist notified.</p></list-item>
<list-item><p>17.7. A dextrose/amino acid PN formulation with the separate infusion of IV fat emulsion should be used in neonatal and infant patients unless the institution identifies a need for total nutrient admixture formulations that will benefit these particular populations.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref>,<xref ref-type="bibr" rid="bibr65-0884533613475822">65</xref></sup></p></list-item>
<list-item><p>17.8. Methods should be established to limit patient exposure to the plasticizer di(2-ethyl-hexyl) phthalate (DEHP) and any other plasticizers that have been identified as potentially harmful while providing EN and PN. Products without the plasticizer DEHP are preferred, especially in patients receiving IV fat emulsions and IV fat emulsion–containing products (eg, propofol).<sup><xref ref-type="bibr" rid="bibr66-0884533613475822">66</xref></sup></p></list-item>
<list-item><p>17.9. Protocols and procedures shall exist to prevent, diagnose, manage, and monitor patient infections caused by contaminated PN formulations or the equipment/devices used to administer PN.<list id="list31-0884533613475822" list-type="simple">
<list-item><p>17.9.1. Infection prevention strategies shall be used to minimize central venous catheter–associated bloodstream infections, including a bundle of targeted, evidence-based catheter insertion practices: use of hand hygiene, maximum sterile barrier precautions during insertion, use of chlorhexidine for skin disinfection before catheter insertion and during central venous catheter dressing change, avoiding the femoral vein insertion site, and prompt removal of unnecessary vascular access devices.<sup><xref ref-type="bibr" rid="bibr67-0884533613475822">67</xref>,<xref ref-type="bibr" rid="bibr68-0884533613475822">68</xref></sup></p></list-item>
<list-item><p>17.9.2. If a multilumen catheter is used, one lumen should be designated exclusively to administer PN. Access ports shall be wiped with an appropriate antiseptic prior to catheter manipulation, and manipulation should be minimized.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref>,<xref ref-type="bibr" rid="bibr67-0884533613475822">67</xref></sup> Co-infusion of fluids or medications into the PN system should be avoided if at all possible. If no other alternatives are available, a pharmacist shall be contacted to investigate the compatibility and stability issues prior to administration.</p></list-item>
<list-item><p>17.9.3. Patient care unit–specific data regarding catheter-associated bloodstream infections should be collected.</p></list-item>
<list-item><p>17.9.4. Administration sets for PN formulations shall include an in-line filter. A 1.2-micron filter may be used for all PN formulations. However, a 0.22-micron filter may be used for dextrose/amino acid formulations.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup></p></list-item>
<list-item><p>17.9.5. IV fat emulsion administered separately from PN formulations should be completed within 12 hours of initiating the infusion. If volume considerations require a longer hang time, the IV fat emulsion dose should be completed within 24 hours of initiating the infusion, divided into two separate doses, each hanging no longer than 12 hours. The IV administration set for the IV fat emulsions shall be replaced within 24 hours of initiating the infusion.<sup><xref ref-type="bibr" rid="bibr67-0884533613475822">67</xref></sup></p></list-item>
</list></p></list-item>
<list-item><p>17.10. A protocol shall be written regarding the maximal rate of administration for IV fat emulsions. Manufacturer recommendations should be considered in formulating this protocol.</p></list-item>
<list-item><p>17.11. Cycling PN formulations should be considered for patients with or at risk of liver dysfunction, on long-term PN, or those who are stable and active and may benefit from infusion-free periods.<sup><xref ref-type="bibr" rid="bibr69-0884533613475822">69</xref></sup></p></list-item>
<list-item><p>17.12. A protocol shall be written to minimize the risk of microbial contamination of EN formulations. Please refer to the “Enteral Nutrition Practice Recommendations,”<sup><xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup> A.S.P.E.N. Clinical Guidelines: Nutrition Support of the Critically Ill Child <sup><xref ref-type="bibr" rid="bibr70-0884533613475822">70</xref></sup> and <italic>Infant Feedings: Guidelines for Preparation of Human Milk and Formula in Health Care Facilities, Second Edition</italic> for details.<sup><xref ref-type="bibr" rid="bibr40-0884533613475822">40</xref></sup></p></list-item>
<list-item><p>17.13. Protocols and procedures should exist to minimize the risk of regurgitation and aspiration of EN formulations.<sup><xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup></p></list-item>
<list-item><p>17.14. A protocol shall exist to minimize the risk of enteral misconnections.<sup><xref ref-type="bibr" rid="bibr71-0884533613475822">71</xref><xref ref-type="bibr" rid="bibr72-0884533613475822"/><xref ref-type="bibr" rid="bibr73-0884533613475822"/>-<xref ref-type="bibr" rid="bibr74-0884533613475822">74</xref></sup><list id="list32-0884533613475822" list-type="simple">
<list-item><p>17.14.1. Enteral access device administration set connectors shall not be purchased that can physically connect with a female Luer IV line connector.<sup><xref ref-type="bibr" rid="bibr72-0884533613475822">72</xref></sup></p></list-item>
<list-item><p>17.14.2. Standard Luer syringes shall not be used to administer oral medications or EN.</p></list-item>
<list-item><p>17.14.3. EN tubes or PN catheters shall be traced from the patient to the point of origin before connecting any new device or infusion.</p></list-item>
<list-item><p>17.14.4. Tubes and catheters with different infusion or drainage purposes should be routed in different, standardized directions (eg, IV lines routed toward the head; enteric lines toward the feet).</p></list-item>
</list></p></list-item>
<list-item><p>17.15. Protocols shall be established for administering medications through an enteral access device.<sup><xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup><list id="list33-0884533613475822" list-type="simple">
<list-item><p>17.15.1. Medications should not be mixed directly with enteral formulations because of potential drug-drug and drug-nutrient interactions and nondelivery of all medications.<sup><xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup></p></list-item>
<list-item><p>17.15.2. Medications should be administered according to current guidelines.<sup><xref ref-type="bibr" rid="bibr51-0884533613475822">51</xref></sup></p></list-item>
<list-item><p>17.15.3. Enteral access device(s) should be flushed appropriately before and after each medication administration and before restarting EN administration, taking into account the patient’s volume status.<sup><xref ref-type="bibr" rid="bibr49-0884533613475822">49</xref></sup></p></list-item></list>
</p></list-item></list>
</sec>
<sec id="section24-0884533613475822">
<title>Standard 18. Adverse Event Management</title>
<p>Clinical protocols for ordering, mixing/compounding, and administering nutrition therapy should be implemented for hospital personnel in order to decrease the risk of adverse events associated with nutrition support therapy. Adverse events, including sentinel events related to the administration of nutrition support therapy and the equipment/access devices, shall be documented and reported per hospital protocol with the goal to prevent similar events in the future and promote a culture of patient safety. The nutrition support team (or committee/group with expertise in nutrition support therapy) should participate in reviewing all such adverse event reports and assist in the development, implementation, and review/revision of relevant nutrition therapy protocols.</p>
</sec></sec>
<sec id="section25-0884533613475822">
<title>CHAPTER V: Monitoring and Reevaluation of the Nutrition Care Plan</title>
<sec id="section26-0884533613475822">
<title>Standard 19. Parameters and Frequency</title>
<p>A plan for monitoring the effect of nutrition interventions should be stated in the nutrition care plan.<sup><xref ref-type="bibr" rid="bibr75-0884533613475822">75</xref></sup> Monitoring parameters are chosen relative to the goals of the nutrition care plan and should include therapeutic and adverse effects and clinical changes that may influence nutrition therapy. The nutrition care plan shall be revised to optimize nutrition support therapy and achieve predetermined outcomes for the patient.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p>
<list id="list34-0884533613475822" list-type="simple">
<list-item><p>19.1. Protocols shall be developed to obtain baseline weight, height, or length and head circumference (if age appropriate) to be plotted on an age- and/or syndrome-appropriate growth curve. There should also be a periodic review of the patient’s growth, development, and clinical and laboratory status. The Centers for Disease Control and Prevention recommends using the World Health Organization (WHO) growth curves for patients under the age of 2 years (see Standard 5.5).<sup><xref ref-type="bibr" rid="bibr76-0884533613475822">76</xref></sup></p></list-item>
<list-item><p>19.2. The frequency of monitoring should depend on gestational age, postnatal age, disease, severity of illness, degree of malnutrition, and level of metabolic stress.<sup><xref ref-type="bibr" rid="bibr75-0884533613475822">75</xref>,<xref ref-type="bibr" rid="bibr77-0884533613475822">77</xref>,<xref ref-type="bibr" rid="bibr78-0884533613475822">78</xref></sup><list id="list35-0884533613475822" list-type="simple">
<list-item><p>19.2.1. Daily or more frequent monitoring may be required for neonates, infants, critically ill patients, and those who have debilitating diseases or infection, are at risk for refeeding complications, are transitioning between PN or EN and oral diet, or have experienced complications associated with nutrition support therapy. Consideration should also be given to the volume of blood required for this monitoring so that only what is necessary is obtained.</p></list-item>
</list></p></list-item>
<list-item><p>19.3. Monitoring parameters should include the following<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref>,<xref ref-type="bibr" rid="bibr75-0884533613475822">75</xref></sup>:<list id="list36-0884533613475822" list-type="bullet">
<list-item><p>Physical assessment, including clinical signs of fluid and nutrient excess or deficiency</p></list-item>
<list-item><p>Vital signs</p></list-item>
<list-item><p>Actual fluid and nutrient intake (oral, enteral, and parenteral) and measuring output (urine, gastrointestinal, wound losses, chest tube drainage, renal replacement effluent)</p></list-item>
<list-item><p>Weight (length and head circumference in infants with prolonged hospital stay). In neonates in particular, and in patients with selected disease states, an assessment of fluid intake and output should accompany an evaluation of weight gain to determine whether the source of the weight increase is fluid or lean body mass.</p></list-item></list>
</p></list-item>
<list-item><p>19.4. Monitoring parameters may include the following<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup>:<list id="list37-0884533613475822" list-type="bullet">
<list-item><p>Laboratory data (complete blood count, serum and capillary glucose, blood urea nitrogen, creatinine, electrolytes [Na, K, Cl, CO<sub>2</sub>], calcium, magnesium, phosphorus, liver enzyme tests, triglycerides, serum proteins, or international normalized ratio [INR]; urine glucose, urine sodium, urine specific gravity). The burden of the test, including consideration of the blood volume required to do the test, should be balanced by the benefit or usefulness of the results, particularly in small infants and those who have been on a stable parenteral or enteral regimen. Trace mineral, vitamin, and carnitine serum concentrations may be evaluated in long-term PN-dependent patients or patients at risk for developing deficiencies or excesses of these particular micronutrients.</p></list-item>
<list-item><p>Medication review</p></list-item>
<list-item><p>Changes in gastrointestinal function indicating tolerance of nutrition therapy (such as ostomy output, stool frequency and consistency, presence of blood or fat in the stool, presence of abdominal distention, increasing abdominal girth, nausea, vomiting)</p></list-item></list>
</p></list-item>
<list-item><p>19.5. Abnormal results in monitoring parameters shall be identified.<sup><xref ref-type="bibr" rid="bibr79-0884533613475822">79</xref></sup> Recommended changes in nutrition support therapy formulation, volume, or route and resulting outcomes shall be documented. Verbal communication shall occur for immediate concerns.</p></list-item></list>
</sec>
<sec id="section27-0884533613475822">
<title>Standard 20. Procedures</title>
<p>Monitoring procedures for nutrition support therapy administration shall include the following:</p>
<list id="list38-0884533613475822" list-type="simple"><list-item><p>20.1. The healthcare provider shall visually inspect the patient’s enteral or parenteral access devices and insertion site.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p></list-item>
<list-item><p>20.2. Inspection of the nutrition support therapy label, expiration date, and infusion rate setting should be done at least daily and at key decision points (eg, at initiation, shift changes, or rate changes).<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup></p></list-item>
<list-item><p>20.3. The healthcare provider shall inspect the nutrition support therapy formulation before administration for signs of gross contamination, particle formation, and phase separation of IV fat emulsions.<sup><xref ref-type="bibr" rid="bibr34-0884533613475822">34</xref></sup></p></list-item>
<list-item><p>20.4. The healthcare provider shall monitor for any signs or symptoms of infusion-related incidents during administration (ie, allergic reaction, phlebitis, etc).</p></list-item>
<list-item><p>20.5. The healthcare provider shall review the patient’s medication profile for the following<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup>:<list id="list39-0884533613475822" list-type="bullet">
<list-item><p>Potential effects on both nutrition and metabolic status</p></list-item>
<list-item><p>Incompatibilities with nutrition support therapy formulation<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p></list-item></list></p></list-item>
</list>
</sec>
<sec id="section28-0884533613475822">
<title>Standard 21. Reevaluation of Nutrition Care Plan</title>
<p>The patient shall be monitored for progress toward short- and long-term objectives as defined in the nutrition care plan.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup></p>
<list id="list40-0884533613475822" list-type="simple"><list-item><p>21.1. Appropriate parameters should be measured serially during nutrition support therapy as outlined in Standard 19 and documented.<sup><xref ref-type="bibr" rid="bibr79-0884533613475822">79</xref></sup></p></list-item>
<list-item><p>21.2. The monitoring parameters should be compared with the goals of the nutrition care plan. If goals are not being met or new problems/risks have arisen, the nutrition care plan should be modified and documented. Adjustments to the nutrition support therapy formulation or volume necessitated by a pediatric patient’s growth shall be identified and recommendations documented. The frequency of comparison should be based on gestational and/or postnatal age (in infants) and the disease or condition, medical stability, tolerance of nutrition therapy, and progress toward achievement of goals.<list id="list41-0884533613475822" list-type="simple">
<list-item><p>21.2.1. Guidelines for frequency of reassessment for given patient populations and nutrition therapies should be developed. Patients hospitalized for more than 5 days shall be reassessed. Patients malnourished at admission should be assessed more frequently.<sup><xref ref-type="bibr" rid="bibr77-0884533613475822">77</xref>,<xref ref-type="bibr" rid="bibr78-0884533613475822">78</xref></sup></p></list-item>
<list-item><p>21.2.2. Revision of the nutrition care plan goals shall involve the patient, caregiver, and healthcare professionals, as appropriate.</p></list-item>
<list-item><p>21.2.3. The cost-effectiveness of the updated nutrition care plan shall be evaluated in terms of the potential risks and benefit for the patient.</p></list-item></list>
</p></list-item>
</list>
</sec></sec>
<sec id="section29-0884533613475822">
<title>CHAPTER VI: Transition of Therapy</title>
<sec id="section30-0884533613475822">
<title>Standard 22. Adequacy of Intake</title>
<p>The pediatric patient should demonstrate appropriate nutrient intake and growth on enterally administered nutrients or oral nutrients prior to the termination of PN and removal of a vascular access device.</p>
<list id="list42-0884533613475822" list-type="simple"><list-item><p>22.1. During the transition to EN, PN should be continued while EN is increased.</p></list-item>
<list-item><p>22.2. Adequate oral intake and growth should be demonstrated and documented prior to terminating nutrition support therapy.</p></list-item>
<list-item><p>22.3. When appropriate, nutrition support therapy should be gradually decreased as oral intake increases so that overall adequate nutrient intake and growth are sustained.</p></list-item></list>
</sec>
<sec id="section31-0884533613475822">
<title>Standard 23. Continuity of Care</title>
<p>To optimize nutrition therapy after hospital discharge, it is essential to develop an ongoing means of communication among all members of the patient care team (ie, patient, parents and/or caregivers, and medical team) and a plan for monitoring nutrition status in the outpatient environment.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup> There shall be continuity of care and active communication with all members of the care team (the patient, parents and/or caregivers, and members of the medical team) to develop a plan for transition of nutrition support therapy.<sup><xref ref-type="bibr" rid="bibr14-0884533613475822">14</xref></sup> If the patient requires extended nutrition support therapy, home care should be considered. Every effort should be made to secure home health care nurses and home infusion agencies that are competent in pediatric care. A.S.P.E.N. standards for home PN and EN support should be followed.<sup><xref ref-type="bibr" rid="bibr80-0884533613475822">80</xref></sup></p>
<list id="list43-0884533613475822" list-type="simple"><list-item><p>23.1. Hospitals should develop protocols for discharge criteria for home EN and PN support.<list id="list44-0884533613475822" list-type="simple">
<list-item><p>23.1.1. Prior to discharge, a designated prescriptive authority should be identified that will monitor the care and communicate with the home care agency.</p></list-item>
<list-item><p>23.1.2. The nutrition support plan for home should be established during hospitalization before discharge (eg, PN cycling, bolus feedings).</p></list-item></list></p></list-item>
<list-item><p>23.2. Patients and/or caregivers should be provided with adequate education in administration and monitoring of home EN and PN prior to hospital discharge to ensure safe administration.</p></list-item></list>
</sec></sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: None declared.</p>
</fn>
<fn fn-type="other">
<p>This article originally appeared online on February 28, 2013.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533613475822">
<label>1.</label>
<citation citation-type="web"><collab>American Society for Parenteral and Enteral Nutrition Board of Directors</collab>. <article-title>Definition of terms, style, and conventions used in A.S.P.E.N. Board of Directors–approved documents</article-title>. <ext-link ext-link-type="uri" xlink:href="http://nutritioncare.org/Professional_Resources/Guidelines_and_Standards/Guidelines/2012_Definitions_of_Terms,_Style,_and_Conventions_Used_in_A_S_P_E_N__Board_of_Directors-Approved_Documents/">http://nutritioncare.org/Professional_Resources/Guidelines_and_Standards/Guidelines/2012_Definitions_of_Terms,_Style,_and_Conventions_Used_in_A_S_P_E_N__Board_of_Directors-Approved_Documents/</ext-link>. Published <month>May</month> <year>2012</year>. <access-date>Accessed May 25, 2012</access-date>.</citation>
</ref>
<ref id="bibr2-0884533613475822">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gamsjäger</surname><given-names>T</given-names></name>
<name><surname>Brenner</surname><given-names>L</given-names></name>
<name><surname>Schaden</surname><given-names>E</given-names></name>
<name><surname>Sitzwohl</surname><given-names>C</given-names></name>
<name><surname>Weinstabl</surname><given-names>C</given-names></name>
</person-group>. <article-title>Cost analysis of two approaches to parenteral nutrition in critically ill children</article-title>. <source>Pediatr Crit Care Med</source>. <year>2009</year>;<volume>10</volume>(<issue>2</issue>):<fpage>163</fpage>-<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr3-0884533613475822">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sánchez</surname><given-names>C</given-names></name>
<name><surname>López-Herce</surname><given-names>J</given-names></name>
<name><surname>Carrillo</surname><given-names>A</given-names></name>
<name><surname>Mencía</surname><given-names>S</given-names></name>
<name><surname>Vigil</surname><given-names>D</given-names></name>
</person-group>. <article-title>Early transpyloric enteral nutrition in critically ill children</article-title>. <source>Nutrition</source>. <year>2007</year>;<volume>23</volume>(<issue>1</issue>):<fpage>16</fpage>-<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr4-0884533613475822">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Oliveira Iglesias</surname><given-names>SB</given-names></name>
<name><surname>Leite</surname><given-names>HP</given-names></name>
<name><surname>Santana</surname><given-names>e</given-names></name>
<name><surname>Meneses</surname><given-names>JF</given-names></name>
<name><surname>de Carvalho</surname><given-names>WB</given-names></name>
</person-group>. <article-title>Enteral nutrition in critically ill children: are prescription and delivery according to their energy requirements?</article-title> <source>Nutr Clin Pract</source>. <year>2007</year>;<volume>22</volume>(<issue>2</issue>):<fpage>233</fpage>-<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr5-0884533613475822">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Skillman</surname><given-names>HE</given-names></name>
<name><surname>Wischmeyer</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Nutrition therapy in critically ill infants and children</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2008</year>;<volume>32</volume>:<fpage>520</fpage>-<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr6-0884533613475822">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rowell</surname><given-names>DS</given-names></name>
<name><surname>Jackson</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>Additional costs of inpatient malnutrition, Victoria, Australia, 2003-2004</article-title>. <source>Eur J Health Econ</source>. <year>2011</year>;<volume>12</volume>(<issue>4</issue>):<fpage>353</fpage>-<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr7-0884533613475822">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sullivan</surname><given-names>PB</given-names></name>
</person-group>. <article-title>Malnutrition in hospitalised children</article-title>. <source>Arch Dis Child</source>. <year>2010</year>;<volume>95</volume>(<issue>7</issue>):<fpage>489</fpage>-<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr8-0884533613475822">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Macias-Rosales</surname><given-names>R</given-names></name>
<name><surname>Vásquez-Garibay</surname><given-names>EM</given-names></name>
<name><surname>Larrosa-Haro</surname><given-names>A</given-names></name>
<name><surname>Rojo-Chávez</surname><given-names>M</given-names></name>
<name><surname>Bernal-Virgen</surname><given-names>A</given-names></name>
<name><surname>Romo-Rubio</surname><given-names>H</given-names></name>
</person-group>. <article-title>Secondary malnutrition and overweight in a pediatric referral hospital: associated factors</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2009</year>;<volume>48</volume>(<issue>2</issue>):<fpage>226</fpage>-<lpage>232</lpage>.</citation>
</ref>
<ref id="bibr9-0884533613475822">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joosten</surname><given-names>KF</given-names></name>
<name><surname>Hulst</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Prevalence of malnutrition in pediatric hospital patients</article-title>. <source>Curr Opin Pediatr</source>. <year>2008</year>;<volume>20</volume>(<issue>5</issue>):<fpage>590</fpage>-<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr10-0884533613475822">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joosten</surname><given-names>KF</given-names></name>
<name><surname>Hulst</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Malnutrition in pediatric hospital patients: current issues</article-title>. <source>Nutrition</source>. <year>2011</year>;<volume>27</volume>(<issue>2</issue>):<fpage>133</fpage>-<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr11-0884533613475822">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Correia</surname><given-names>MI</given-names></name>
<name><surname>Campos</surname><given-names>AC</given-names></name>
</person-group>; <collab>ELAN Cooperative Study</collab>. <article-title>Prevalence of hospital malnutrition in Latin America: the multicenter ELAN study</article-title>. <source>Nutrition</source>. <year>2003</year>;<volume>19</volume>(<issue>10</issue>):<fpage>823</fpage>-<lpage>825</lpage>.</citation>
</ref>
<ref id="bibr12-0884533613475822">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campanozzi</surname><given-names>A</given-names></name>
<name><surname>Russo</surname><given-names>M</given-names></name>
<name><surname>Catucci</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Hospital-acquired malnutrition in children with mild clinical conditions</article-title>. <source>Nutrition</source>. <year>2009</year>;<volume>25</volume>(<issue>5</issue>):<fpage>540</fpage>-<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr13-0884533613475822">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agostoni</surname><given-names>C</given-names></name>
<name><surname>Axelson</surname><given-names>I</given-names></name>
<name><surname>Colomb</surname><given-names>V</given-names></name><etal/>
</person-group>; <collab>ESPGHAN Committee on Nutrition</collab>. <article-title>The need for nutrition support teams in pediatric units: a commentary by the ESPGHAN committee on nutrition</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2005</year>;<volume>41</volume>(<issue>1</issue>):<fpage>8</fpage>-<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr14-0884533613475822">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ukleja</surname><given-names>A</given-names></name>
<name><surname>Freeman</surname><given-names>KL</given-names></name>
<name><surname>Gilbert</surname><given-names>K</given-names></name><etal/>
</person-group>; <collab>Task Force on Standards for Nutrition Support: Adult Hospital Patients, and the American Society for Parenteral and Enteral Nutrition Board of Directors</collab>. <article-title>Standards for nutrition support: adult hospitalized patients</article-title>. <source>Nutr Clin Pract</source>. <year>2010</year>;<volume>25</volume>(<issue>4</issue>):<fpage>403</fpage>-<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr15-0884533613475822">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mascarenhas</surname><given-names>MR</given-names></name>
<name><surname>August</surname><given-names>DA</given-names></name>
<name><surname>DeLegge</surname><given-names>MH</given-names></name>
<etal/></person-group>; <collab>Task Force on Standards for Nutrition Support Physicians and the American Society for Parenteral and Enteral Nutrition Board of Directors</collab>. <article-title>Standards of practice for nutrition support physicians</article-title>. <source>Nutr Clin Pract</source>. <year>2012</year>;<volume>27</volume>(<issue>2</issue>):<fpage>295</fpage>-<lpage>299</lpage>.</citation>
</ref>
<ref id="bibr16-0884533613475822">
<label>16.</label>
<citation citation-type="journal"><collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors and Nurses Standards Revision Task Force, DiMaria-Ghalili RA, Bankhead R, et al</collab>. <article-title>Standards of practice for nutrition support nurses</article-title>. <source>Nutr Clin Pract</source>. <year>2007</year>;<volume>22</volume>(<issue>4</issue>):<fpage>458</fpage>-<lpage>465</lpage>.</citation>
</ref>
<ref id="bibr17-0884533613475822">
<label>17.</label>
<citation citation-type="journal"><collab>Task Force of A.S.P.E.N., American Dietetic Association Dietitians in Nutrition Support Dietetic Practice Group, Russell M, Stieber M, Brantley S, et al. American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)</collab> <article-title>and American Dietetic Association (ADA): standards of practice and standards of professional performance for registered dietitians (generalist, specialty, and advanced) in nutrition support</article-title>. <source>Nutr Clin Pract</source>. <year>2007</year>;<volume>22</volume>(<issue>5</issue>):<fpage>558</fpage>-<lpage>586</lpage>.</citation>
</ref>
<ref id="bibr18-0884533613475822">
<label>18.</label>
<citation citation-type="journal"><collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Task Force for Revision of Nutrition Support Pharmacist Standards, Rollins C, Durfee SM, Holcombe BJ, et al</collab>. <article-title>Standards of practice for nutrition support pharmacists</article-title>. <source>Nutr Clin Pract</source>. <year>2008</year>;<volume>23</volume>:<fpage>189</fpage>-<lpage>194</lpage>.</citation>
</ref>
<ref id="bibr19-0884533613475822">
<label>19.</label>
<citation citation-type="journal">
<collab>A.S.P.E.N. Practice Management Task Force</collab>, <person-group person-group-type="author">
<name><surname>Delegge</surname><given-names>M</given-names></name>
<name><surname>Wooley</surname><given-names>JA</given-names></name>
<name><surname>Guenter</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>The state of nutrition support teams and update on current models for providing nutrition support therapy to patients</article-title>. <source>Nutr Clin Pract</source>. <year>2010</year>;<volume>25</volume>(<issue>1</issue>):<fpage>76</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr20-0884533613475822">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ogden</surname><given-names>CL</given-names></name>
<name><surname>Carroll</surname><given-names>MD</given-names></name>
<name><surname>Flegal</surname><given-names>KM</given-names></name>
</person-group>. <article-title>High body mass index for age among US children and adolescents, 2003-2006</article-title>. <source>JAMA</source>. <year>2008</year>;<volume>299</volume>(<issue>20</issue>):<fpage>2401</fpage>-<lpage>2405</lpage>.</citation>
</ref>
<ref id="bibr21-0884533613475822">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flegal</surname><given-names>KM</given-names></name>
<name><surname>Graubard</surname><given-names>BI</given-names></name>
<name><surname>Williamson</surname><given-names>DF</given-names></name>
<name><surname>Gail</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Cause-specific excess deaths associated with underweight, overweight, and obesity</article-title>. <source>JAMA</source>. <year>2007</year>;<volume>298</volume>(<issue>17</issue>):<fpage>2028</fpage>-<lpage>2037</lpage>.</citation>
</ref>
<ref id="bibr22-0884533613475822">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eaton</surname><given-names>DK</given-names></name>
<name><surname>Kann</surname><given-names>L</given-names></name>
<name><surname>Kinchen</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Youth risk behavior surveillance—United States, 2007</article-title>. <source>MMWR Surveill Summ</source>. <year>2008</year>;<volume>57</volume>(<issue>4</issue>):<fpage>1</fpage>-<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr23-0884533613475822">
<label>23.</label>
<citation citation-type="book"><collab>Joint Commission on Accreditation of Healthcare Organizations</collab>. <source>Comprehensive Accreditation Manual for Hospitals: The Official Handbook</source>. <publisher-loc>Oakbrook Terrace, IL</publisher-loc>: <publisher-name>Joint Commission Resources</publisher-name>; <year>2009</year>. <fpage>PC.01.02.01</fpage>, <lpage>PC 01.02.03</lpage>.</citation>
</ref>
<ref id="bibr24-0884533613475822">
<label>24.</label>
<citation citation-type="book"><collab>A.S.P.E.N. Board of Directors</collab>. <article-title>Board of Directors</article-title>. <source>Clinical Pathways and Algorithms for Delivery of Parenteral and Enteral Nutrition Support in Adults</source>. <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>American Society for Parenteral and Enteral Nutrition</publisher-name>; <year>1998</year>.</citation>
</ref>
<ref id="bibr25-0884533613475822">
<label>25.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Klotz</surname><given-names>KA</given-names></name>
<name><surname>Wessel</surname><given-names>JJ</given-names></name>
<name><surname>Hennies</surname><given-names>GA</given-names></name>
</person-group>. <article-title>Goals of pediatric nutrition support and nutrition assessment</article-title>. In: <person-group person-group-type="editor">
<name><surname>Merritt</surname><given-names>R</given-names></name>
</person-group>, ed. <source>The A.S.P.E.N. Nutrition Support Practice Manual</source>. <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>American Society for Parenteral and Enteral Nutrition</publisher-name>; <year>1998</year>;<fpage>23-1</fpage>–<lpage>23-13</lpage>.</citation>
</ref>
<ref id="bibr26-0884533613475822">
<label>26.</label>
<citation citation-type="book"><source>International Dietetics &amp; Nutrition Terminology (IDNT) Reference Manual</source>. <edition>4th ed.</edition> <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>Academy of Nutrition and Dietetics</publisher-name>; <year>2010</year>.</citation>
</ref>
<ref id="bibr27-0884533613475822">
<label>27.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Carney</surname><given-names>LN</given-names></name>
<name><surname>Blair</surname><given-names>J</given-names></name>
</person-group>. <article-title>Assessment of nutrition status by age and determining nutrient needs</article-title>. In: <person-group person-group-type="editor">
<name><surname>Corkins</surname><given-names>MR</given-names></name>
</person-group>, ed. <source>The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum</source>. <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>American Society for Parenteral and Enteral Nutrition</publisher-name>; <volume>2010</volume>:<fpage>409</fpage>-<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr28-0884533613475822">
<label>28.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Soldin</surname><given-names>SJ</given-names></name>
<name><surname>Brugnara</surname><given-names>C</given-names></name>
<name><surname>Wong</surname><given-names>EC</given-names></name>
</person-group>, eds. <source>Pediatric Reference Intervals</source>. <edition>6th ed.</edition> <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>AACC Press</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr29-0884533613475822">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joosten</surname><given-names>KF</given-names></name>
<name><surname>Hulst</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Malnutrition in pediatric hospital patients: current issues</article-title>. <source>Nutrition</source>. <year>2011</year>;<volume>27</volume>(<issue>2</issue>):<fpage>133</fpage>-<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr30-0884533613475822">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kamen</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Impaired development of oral-motor functions required for normal oral feeding as a consequence of tube feeding during infancy</article-title>. <source>Adv Perit Dial</source>. <year>1990</year>;<volume>6</volume>:<fpage>276</fpage>-<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr31-0884533613475822">
<label>31.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Cox</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Obesity</article-title>. In: <person-group person-group-type="editor">
<name><surname>Cox</surname><given-names>JH</given-names></name>
</person-group>, ed. <source>Nutrition Manual for At-Risk Infants and Toddlers</source>. <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>Precept Press</publisher-name>; <year>1997</year>.</citation>
</ref>
<ref id="bibr32-0884533613475822">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Collier</surname><given-names>PE</given-names></name>
<name><surname>Goodman</surname><given-names>GB</given-names></name>
</person-group>. <article-title>Cardiac tamponade caused by central venous catheter perforation of the heart: a preventable complication</article-title>. <source>J Am Coll Surg</source>. <year>1995</year>;<volume>181</volume>(<issue>5</issue>):<fpage>459</fpage>-<lpage>463</lpage>.</citation>
</ref>
<ref id="bibr33-0884533613475822">
<label>33.</label>
<citation citation-type="journal"><collab>Infusion Nurses Society</collab>. <article-title>Infusion nursing standards of practice</article-title>. <source>J Infus Nurs</source>. <year>2006</year>;<volume>29</volume>(<issue>1</issue>)(<supplement>suppl</supplement>):<fpage>S1</fpage>-<lpage>S92</lpage>.</citation>
</ref>
<ref id="bibr34-0884533613475822">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mirtallo</surname><given-names>J</given-names></name>
<name><surname>Canada</surname><given-names>T</given-names></name>
<name><surname>Johnson</surname><given-names>D</given-names></name>
<etal/></person-group>; <collab>Task Force for the Revision of Safe Practices for Parenteral Nutrition</collab>. <article-title>Safe practices for parenteral nutrition</article-title> [published correction appears in <italic>JPEN J Parenter Enteral Nutr</italic>. <year>2006</year>;<volume>30</volume>(<issue>2</issue>):<fpage>177</fpage>]. <source>JPEN J Parenter Enteral Nutr</source>. <year>2004</year>;<volume>28</volume>(<issue>6</issue>):<fpage>S39</fpage>-<lpage>S70</lpage>.</citation>
</ref>
<ref id="bibr35-0884533613475822">
<label>35.</label>
<citation citation-type="book"><collab>United States Pharmacopeial Convention, Inc</collab>. <source>&lt;797&gt; Pharmaceutical Compounding—Sterile Preparations</source>. <publisher-loc>United States Pharmacopeia 34—National Formulary 29. Rockville, MD</publisher-loc>: <publisher-name>The United States Pharmacopeial Convention</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr36-0884533613475822">
<label>36.</label>
<citation citation-type="journal"><collab>ASHP guidelines on the safe use of automated compounding devices for the preparation of parenteral nutrition admixtures</collab>. <article-title>Developed through the ASHP Council on Professional Affairs and approved by the ASHP Board of Directors on April 27, 2000</article-title>. <source>Am J Health Syst Pharm</source>. <year>2000</year>;<volume>57</volume>(<issue>14</issue>):<fpage>1343</fpage>-<lpage>1348</lpage>.</citation>
</ref>
<ref id="bibr37-0884533613475822">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crill</surname><given-names>CM</given-names></name>
<name><surname>Hak</surname><given-names>EB</given-names></name>
<name><surname>Robinson</surname><given-names>LA</given-names></name>
<name><surname>Helms</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Evaluation of microbial contamination associated with different preparation methods for neonatal intravenous fat emulsion infusion</article-title>. <source>Am J Health Syst Pharm</source>. <year>2010</year>;<volume>67</volume>(<issue>11</issue>):<fpage>914</fpage>-<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr38-0884533613475822">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Charney</surname><given-names>PJ</given-names></name>
</person-group>, <collab>A.S.P.E.N. Aluminum Task Force</collab>. <article-title>statement on aluminum in parenteral nutrition solutions</article-title>. <source>Nutr Clin Pract</source>. <year>2004</year>;<volume>19</volume>(<issue>4</issue>):<fpage>416</fpage>-<lpage>417</lpage>.</citation>
</ref>
<ref id="bibr39-0884533613475822">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Speerhas</surname><given-names>RA</given-names></name>
<name><surname>Seidner</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Measured versus estimated aluminum content of parenteral nutrient solutions</article-title>. <source>Am J Health Syst Pharm</source>. <year>2007</year>;<volume>64</volume>(<issue>7</issue>): <fpage>740</fpage>-<lpage>746</lpage>.</citation>
</ref>
<ref id="bibr40-0884533613475822">
<label>40.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Robbins</surname><given-names>ST</given-names></name>
<name><surname>Meyers</surname><given-names>R</given-names></name>
</person-group>, eds. <source>Infant Feedings: Guidelines for Preparation of Human Milk and Formula in Health Care Facilities</source>. <edition>2nd ed.</edition> <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>American Dietetic Association</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr41-0884533613475822">
<label>41.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>F</given-names></name>
</person-group>. <source>Best Practice for Expressing, Storing and Handling Human Milk</source>. <edition>3rd ed.</edition> <publisher-loc>Fort Worth, TX</publisher-loc>: <publisher-name>Human Milk Banking Association of North America</publisher-name>; <year>2011</year>.</citation>
</ref>
<ref id="bibr42-0884533613475822">
<label>42.</label>
<citation citation-type="book"><collab>Association of Women’s Health, Obstetric, and Neonatal Nurses (AWHONN)</collab>. <source>Evidence Based Clinical Practice Guideline: Breastfeeding Support: Prenatal Care Through the First Year</source>. <edition>2nd ed.</edition> <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>AWOHNN</publisher-name>; <year>2007</year>.</citation>
</ref>
<ref id="bibr43-0884533613475822">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>MR</given-names></name>
<name><surname>Batista</surname><given-names>CR</given-names></name>
<name><surname>Aidoo</surname><given-names>KE</given-names></name>
</person-group>. <article-title>Application of Hazard Analysis Critical Control Points system to enteral tube feeding in hospital</article-title>. <source>J Hum Nutr Diet</source>. <year>2001</year>;<volume>14</volume>(<issue>5</issue>):<fpage>397</fpage>-<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr44-0884533613475822">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>MR</given-names></name>
<name><surname>Bonelli</surname><given-names>R</given-names></name>
<name><surname>Aidoo</surname><given-names>KE</given-names></name>
<name><surname>Batista</surname><given-names>CR</given-names></name>
</person-group>. <article-title>Microbiological quality of reconstituted enteral formulations used in hospitals</article-title>. <source>Nutrition</source>. <year>2000</year>;<volume>16</volume>(<issue>9</issue>):<fpage>729</fpage>-<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr45-0884533613475822">
<label>45.</label>
<citation citation-type="gov"><collab>U.S. Food and Drug Administration, National Advisory Committee on Microbiological Criteria for Foods. Hazard analysis and critical control point principles and application guidelines. Adopted</collab> <month>August</month> <day>14</day>, <year>1997</year>. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Food/FoodSafety/HazardAnalysisCriticalControlPointsHACCP/HACCPPrinciplesApplicationGuidelines/default.htm">http://www.fda.gov/Food/FoodSafety/HazardAnalysisCriticalControlPointsHACCP/HACCPPrinciplesApplicationGuidelines/default.htm</ext-link>. <access-date>Accessed June 21, 2011</access-date>.</citation>
</ref>
<ref id="bibr46-0884533613475822">
<label>46.</label>
<citation citation-type="web"><collab>Institute for Safe Medication Practices</collab>. <article-title>Fatal 1,000-fold overdoses can occur, particularly in neonates, by transposing mcg and mg</article-title>. <source>ISMP Medication Safety Alert!</source> <ext-link ext-link-type="uri" xlink:href="http://www.ismp.org/newsletters/acutecare/articles/20070906.asp">http://www.ismp.org/newsletters/acutecare/articles/20070906.asp</ext-link>. Published <year>2007</year>. <access-date>Accessed May 30, 2012</access-date>.</citation>
</ref>
<ref id="bibr47-0884533613475822">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>RS</given-names></name>
<name><surname>Jurgens</surname><given-names>RW</given-names></name>
<name><surname>Sturgeon</surname><given-names>R</given-names></name>
<name><surname>Athanikar</surname><given-names>N</given-names></name>
<name><surname>Welco</surname><given-names>A</given-names></name>
<name><surname>Van Leuven</surname><given-names>M</given-names></name>
</person-group>. <article-title>Compatibility of calcium chloride and calcium gluconate with sodium phosphate in a mixed TPN solution</article-title>. <source>Am J Hosp Pharm</source>. <year>1980</year>;<volume>37</volume>(<issue>5</issue>): <fpage>673</fpage>-<lpage>674</lpage>.</citation>
</ref>
<ref id="bibr48-0884533613475822">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greene</surname><given-names>HL</given-names></name>
<name><surname>Hambidge</surname><given-names>KM</given-names></name>
<name><surname>Schanler</surname><given-names>R</given-names></name>
<name><surname>Tsang</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Guidelines for the use of vitamins, trace elements, calcium, magnesium, and phosphorous in infants and children receiving total parenteral nutrition: report of the Subcommittee on Pediatric Parenteral Nutrient Requirements from the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition</article-title>. <source>Am J Clin Nutr</source>. <year>1998</year>;<volume>48</volume>(<issue>5</issue>):<fpage>1324</fpage>-<lpage>1342</lpage>.</citation>
</ref>
<ref id="bibr49-0884533613475822">
<label>49.</label>
<citation citation-type="web"><article-title>A.S.P.E.N. Parenteral Nutrition Multivitamin Product Shortage Considerations</article-title>. <month>May</month> <year>2012</year>. <ext-link ext-link-type="uri" xlink:href="http://www.nutritioncare.org/Professional_Resources/Drug_Shortages_Update/">http://www.nutritioncare.org/Professional_Resources/Drug_Shortages_Update/</ext-link>. <access-date>Accessed November 17, 2012</access-date>.</citation>
</ref>
<ref id="bibr50-0884533613475822">
<label>50.</label>
<citation citation-type="web"><article-title>A.S.P.E.N. Parenteral Nutrition Trace Element Product Shortage Considerations</article-title> <year>2011</year>. <ext-link ext-link-type="uri" xlink:href="http://www.nutritioncare.org/Professional_Resources/Drug_Shortages_Update/">http://www.nutritioncare.org/Professional_Resources/Drug_Shortages_Update/</ext-link>. <access-date>Accessed November 17, 2012</access-date>.</citation>
</ref>
<ref id="bibr51-0884533613475822">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bankhead</surname><given-names>R</given-names></name>
<name><surname>Boullata</surname><given-names>J</given-names></name>
<name><surname>Brantley</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Enteral nutrition practice recommendations</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>(<issue>2</issue>):<fpage>122</fpage>-<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr52-0884533613475822">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McClave</surname><given-names>SA</given-names></name>
<name><surname>DeMeo</surname><given-names>MT</given-names></name>
<name><surname>DeLegge</surname><given-names>MH</given-names></name>
<etal/></person-group>. <article-title>North American Summit on Aspiration in the critically ill patient: consensus statement</article-title>. <source>JPEN J Parenteral Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>(<issue>6</issue>)(<supplement>suppl</supplement>):<fpage>S80</fpage>-<lpage>S85</lpage>.</citation>
</ref>
<ref id="bibr53-0884533613475822">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brady</surname><given-names>SL</given-names></name>
<name><surname>Hildner</surname><given-names>CD</given-names></name>
<name><surname>Hutchins</surname><given-names>BF</given-names></name>
</person-group>. <article-title>Simultaneous videofluoroscopic swallow study and modified Evans blue dye procedure: an evaluation of blue dye visualization in cases of known aspiration</article-title>. <source>Dysphagia</source>. <year>1999</year>;<volume>14</volume>(<issue>3</issue>):<fpage>146</fpage>-<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr54-0884533613475822">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metheny</surname><given-names>NA</given-names></name>
<name><surname>Dahms</surname><given-names>TE</given-names></name>
<name><surname>Stewart</surname><given-names>BJ</given-names></name>
<etal/></person-group>. <article-title>Efficacy of dye-stained enteral formula in detecting pulmonary aspiration</article-title>. <source>Chest</source>. <year>2002</year>;<volume>122</volume>(<issue>1</issue>):<fpage>276</fpage>-<lpage>281</lpage>.</citation>
</ref>
<ref id="bibr55-0884533613475822">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Metheny</surname><given-names>NA</given-names></name>
<name><surname>Aud</surname><given-names>MA</given-names></name>
<name><surname>Wunderlich</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>A survey of bedside methods used to detect pulmonary aspiration of enteral formula in intubated tube fed patients</article-title>. <source>Am J Crit Care</source>. <year>1999</year>;<volume>8</volume>(<issue>3</issue>):<fpage>168</fpage>-<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr56-0884533613475822">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Potts</surname><given-names>RG</given-names></name>
<name><surname>Zaroukian</surname><given-names>MH</given-names></name>
<name><surname>Guerrero</surname><given-names>PA</given-names></name>
<name><surname>Baker</surname><given-names>CD</given-names></name>
</person-group>. <article-title>Comparison of blue dye visualization and glucose oxidase test strip methods for detecting pulmonary aspiration of enteral feedings in intubated adults</article-title>. <source>Chest</source>. <year>1993</year>;<volume>103</volume>(<issue>1</issue>):<fpage>117</fpage>-<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr57-0884533613475822">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thompson-Henry</surname><given-names>S</given-names></name>
<name><surname>Braddock</surname><given-names>B</given-names></name>
</person-group>. <article-title>The modified Evan’s blue dye procedure fails to detect aspiration in the tracheostomized patient: five case reports</article-title>. <source>Dysphagia</source>. <year>1995</year>;<volume>10</volume>(<issue>3</issue>):<fpage>172</fpage>-<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr58-0884533613475822">
<label>58.</label>
<citation citation-type="book"><collab>U.S. Food and Drug Administration (FDA)</collab>. <source>FDA Public Health Advisory: Subject: Reports of Blue Dye Discoloration and Death in Patients Receiving Enteral Feedings Tinted with the Dye, FD&amp;C blue No. 1</source>. <publisher-loc>Rockville, MD</publisher-loc>: <publisher-name>FDA</publisher-name>; <month>September</month> <volume>29</volume>, <year>2003</year>.</citation>
</ref>
<ref id="bibr59-0884533613475822">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maloney</surname><given-names>JP</given-names></name>
<name><surname>Halbower</surname><given-names>AC</given-names></name>
<name><surname>Fouty</surname><given-names>BF</given-names></name>
<etal/></person-group>. <article-title>Systemic absorption of food dye in patients with sepsis</article-title>. <source>N Engl J Med</source>. <year>2000</year>;<volume>343</volume>(<issue>14</issue>):<fpage>1047</fpage>-<lpage>1048</lpage>.</citation>
</ref>
<ref id="bibr60-0884533613475822">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maloney</surname><given-names>JP</given-names></name>
<name><surname>Ryan</surname><given-names>TA</given-names></name>
<name><surname>Brasel</surname><given-names>KJ</given-names></name>
<etal/></person-group>. <article-title>Food dye use in enteral feedings: a review and a call for a moratorium</article-title>. <source>Nutr Clin Pract</source>. <year>2002</year>;<volume>17</volume>(<issue>3</issue>):<fpage>169</fpage>-<lpage>181</lpage>.</citation>
</ref>
<ref id="bibr61-0884533613475822">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maloney</surname><given-names>JP</given-names></name>
<name><surname>Ryan</surname><given-names>TA</given-names></name>
</person-group>. <article-title>Detection of aspiration in enterally fed patients: a requiem for bedside monitors of aspiration</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>(6)(<supplement>suppl</supplement>):<fpage>S34</fpage>-<lpage>S41</lpage>.</citation>
</ref>
<ref id="bibr62-0884533613475822">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reyes</surname><given-names>FG</given-names></name>
<name><surname>Valim</surname><given-names>MF</given-names></name>
<name><surname>Vercesi</surname><given-names>AE</given-names></name>
</person-group>. <article-title>Effect of organic synthetic food colours on mitochondrial respiration</article-title>. <source>Food Addit Contam</source>. <year>1996</year>;<volume>13</volume>(<issue>1</issue>):<fpage>5</fpage>-<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr63-0884533613475822">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albert</surname><given-names>M</given-names></name>
<name><surname>Lessin</surname><given-names>MS</given-names></name>
<name><surname>Gilchrist</surname><given-names>BF</given-names></name>
</person-group>. <article-title>Methylene blue: dangerous dye for neonates</article-title>. <source>J Pediatr Surg</source>. <year>2003</year>;<volume>38</volume>(<issue>8</issue>):<fpage>1244</fpage>-<lpage>1245</lpage>.</citation>
</ref>
<ref id="bibr64-0884533613475822">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>File</surname><given-names>TM</given-names></name>
<name><surname>Tan</surname><given-names>JS</given-names></name>
<name><surname>Thomson</surname><given-names>RB</given-names></name>
<name><surname>Stephens</surname><given-names>C</given-names></name>
<name><surname>Thompson</surname><given-names>P</given-names></name>
</person-group>. <article-title>An outbreak of <italic>Pseudomonas aeruginosa</italic> ventilator-associated respiratory infection due to contaminated food coloring dye: further evidence of the significance of gastric colonization preceding nosocomial pneumonia</article-title>. <source>Infect Control Hosp Epidemiol</source>. <year>1995</year>;<volume>16</volume>(<issue>7</issue>):<fpage>417</fpage>-<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr65-0884533613475822">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bullock</surname><given-names>L</given-names></name>
<name><surname>Fitzgerald</surname><given-names>JF</given-names></name>
<name><surname>Walter</surname><given-names>WV</given-names></name>
</person-group>. <article-title>Emulsion stability in total nutrient admixtures containing a pediatric amino acid formulation</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1992</year>;<volume>16</volume>(<issue>1</issue>):<fpage>64</fpage>-<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr66-0884533613475822">
<label>66.</label>
<citation citation-type="gov"><collab>U.S. Department of Health and Human Services</collab>. <source>Toxicological profile for Di(2-ethylhexl)phthalate</source>. <month>September</month> <year>2002</year>. <ext-link ext-link-type="uri" xlink:href="http://www.atsdr.cdc.gov/toxprofiles/tp9.pdf">http://www.atsdr.cdc.gov/toxprofiles/tp9.pdf</ext-link>. <access-date>Accessed June 20, 2012</access-date>.</citation>
</ref>
<ref id="bibr67-0884533613475822">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Grady</surname><given-names>NP</given-names></name>
<name><surname>Alexander</surname><given-names>M</given-names></name>
<name><surname>Burns</surname><given-names>LA</given-names></name>
<etal/></person-group>; <collab>Healthcare Infection Control Practices Advisory Committee</collab>. <article-title>Guidelines for the prevention of intravascular catheter-related infections</article-title>. <source>Am J Infect Control</source>. <year>2011</year>;<volume>39</volume>(<issue>4</issue>)(<supplement>suppl 1</supplement>):<fpage>S1</fpage>-<lpage>S34</lpage>.</citation>
</ref>
<ref id="bibr68-0884533613475822">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittiruti</surname><given-names>M</given-names></name>
<name><surname>Hamilton</surname><given-names>H</given-names></name>
<name><surname>Biffi</surname><given-names>R</given-names></name>
<name><surname>MacFie</surname><given-names>J</given-names></name>
<name><surname>Pertkiewicz</surname><given-names>M</given-names></name>
</person-group>. <article-title>ESPEN Guidelines on Parenteral Nutrition: central venous catheters (access, care, diagnosis and therapy of complications)</article-title>. <source>Clin Nutr</source>. <year>2009</year>;<volume>28</volume>(<issue>4</issue>):<fpage>365</fpage>-<lpage>377</lpage>.</citation>
</ref>
<ref id="bibr69-0884533613475822">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>AR</given-names></name>
<name><surname>Goldin</surname><given-names>AB</given-names></name>
<name><surname>Koopmeiners</surname><given-names>JS</given-names></name>
<name><surname>Stevens</surname><given-names>J</given-names></name>
<name><surname>Waldhausen</surname><given-names>JH</given-names></name>
<name><surname>Kim</surname><given-names>SS</given-names></name>
</person-group>. <article-title>The association of cyclic parenteral nutrition and decreased incidence of cholestatic liver disease in patients with gastroschisis</article-title>. <source>J Pediatr Surg</source>. <year>2009</year>;<volume>44</volume>(<issue>1</issue>):<fpage>183</fpage>-<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr70-0884533613475822">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>NM</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
</person-group>, <collab>A.S.P.E.N. Board of Directors. A.S.P.E.N</collab>. <article-title>Clinical Guidelines: nutrition support of the critically ill child</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>(<issue>3</issue>):<fpage>260</fpage>-<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr71-0884533613475822">
<label>71.</label>
<citation citation-type="journal"><collab>Association for the Advancement of Medical Instrumentation</collab>. <article-title>Enteral feeding set connectors and adapters</article-title>. <source>Nutr Clin Pract</source>. <year>1997</year>;<volume>12</volume>(<issue>1</issue>):<supplement>suppl i-vi</supplement>;<fpage>1</fpage>-<lpage>2</lpage>.</citation>
</ref>
<ref id="bibr72-0884533613475822">
<label>72.</label>
<citation citation-type="web"><collab>The Joint Commission. Sentinel event alert, tubing misconnections—a persistent and potentially deadly occurrence</collab>. Issue 36. <ext-link ext-link-type="uri" xlink:href="http://www.jointcommission.org/sentinel_event_alert_issue_36_tubing_misconnections—a_persistent_and_potentially_deadly_occurrence/">http://www.jointcommission.org/sentinel_event_alert_issue_36_tubing_misconnections—a_persistent_and_potentially_deadly_occurrence/</ext-link>. Published <year>2006</year>. <access-date>Accessed July 1, 2012</access-date>.</citation>
</ref>
<ref id="bibr73-0884533613475822">
<label>73.</label>
<citation citation-type="journal">
<collab>ECRI</collab>. <article-title>Preventing misconnections of lines and cables</article-title>. <source>Health Devices</source>. <year>2006</year>;<volume>35</volume>(<issue>3</issue>):<fpage>81</fpage>-<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr74-0884533613475822">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guenter</surname><given-names>P</given-names></name>
<name><surname>Hicks</surname><given-names>RW</given-names></name>
<name><surname>Simmons</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Enteral feeding misconnections: a consortium position statement</article-title>. <source>Jt Comm J Qual Patient Saf</source>. <year>2008</year>;<volume>34</volume>(<issue>5</issue>):<fpage>285</fpage>-<lpage>292</lpage>.</citation>
</ref>
<ref id="bibr75-0884533613475822">
<label>75.</label>
<citation citation-type="journal"><collab>A.S.P.E.N. Board of Directors and the Clinical Guidelines Task Force</collab>. <article-title>Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients</article-title> [published correction appears in <italic>JPEN J Parenter Enteral Nutr</italic>. <year>2002</year>;<volume>26</volume>(<issue>2</issue>):<fpage>144</fpage>]. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>(<issue>1</issue>)(<supplement>suppl</supplement>):<fpage>1SA</fpage>-<lpage>138SA</lpage>.</citation>
</ref>
<ref id="bibr76-0884533613475822">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grummer-Strawn</surname><given-names>LM</given-names></name>
<name><surname>Reinold</surname><given-names>C</given-names></name>
<name><surname>Krebs</surname><given-names>NF</given-names></name>
</person-group>; <collab>Centers for Disease Control and Prevention (CDC)</collab>. <article-title>Use of World Health Organization and CDC growth charts for children aged 0-59 months in the United States</article-title>. <source>MMWR Recomm Rep</source>. <year>2010</year>;<volume>59</volume>(<issue>RR-9</issue>):<fpage>1</fpage>-<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr77-0884533613475822">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oztürk</surname><given-names>Y</given-names></name>
<name><surname>Büyükgebiz</surname><given-names>B</given-names></name>
<name><surname>Arslan</surname><given-names>N</given-names></name>
<name><surname>Ellidokuz</surname><given-names>H</given-names></name>
</person-group>. <article-title>Effects of hospital stay on nutritional anthropometric data in Turkish children</article-title>. <source>J Trop Pediatr</source>. <year>2003</year>;<volume>49</volume>(<issue>3</issue>):<fpage>189</fpage>-<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr78-0884533613475822">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campanozzi</surname><given-names>A</given-names></name>
<name><surname>Russo</surname><given-names>M</given-names></name>
<name><surname>Catucci</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Hospital-acquired malnutrition in children with mild clinical conditions</article-title>. <source>Nutrition</source>. <year>2009</year>;<volume>25</volume>(<issue>5</issue>):<fpage>540</fpage>-<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr79-0884533613475822">
<label>79.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Szeszycki</surname><given-names>E</given-names></name>
<name><surname>Cruse</surname><given-names>W</given-names></name>
<name><surname>Strup</surname><given-names>M</given-names></name>
</person-group>. <article-title>Evaluation and monitoring of pediatric patients receiving specialized nutrition support</article-title>. In: <person-group person-group-type="editor">
<name><surname>Corkins</surname><given-names>MR</given-names></name>
</person-group>, ed. <source>The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum</source>. <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>American Society for Parenteral and Enteral Nutrition</publisher-name>; <volume>2010</volume>:<fpage>460</fpage>-<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr80-0884533613475822">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kovacevich</surname><given-names>DS</given-names></name>
<name><surname>Frederick</surname><given-names>A</given-names></name>
<name><surname>Kelly</surname><given-names>D</given-names></name>
<etal/></person-group>; <collab>American Society for Parenteral and Enteral Nutrition Board of Directors; Standards for Specialized Nutrition Support Task Force</collab>. <article-title>Standards for specialized nutrition support: home care patients</article-title>. <source>Nutr Clin Pract</source>. <year>2005</year>;<volume>20</volume>(<issue>5</issue>):<fpage>579</fpage>-<lpage>590</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>